Kornimate/medical-research-clean huggingface dataset:
study of homing of labelled stem cells in human heart.

Conditions: Homing of Stem Cells in the Infarct Area.

Summary: one of the challenges of stem cell therapy is to understand the fate of the injected stem cell. by labelling various stem cells with radioisotopes their fate (homing) can be demonstrated. in this study, we will develop and refine the existing techniques of stem cell labelling to various subtypes of stem cells namely- freshly aspirated bone marrow cells, cryopreserved bone marrow cells, g-csf mobilized peripheral blood stem cells and umbilical cord cells. after testing the labelling efficacy and viability, these cells will be injected in to the coronary arteries of patients with myocardial infarction who have undergone a successful revascularization either by angioplasty or thrombolysis. homing of stem cells will be demonstrated by nuclear scan after the procedure. we are adapting techniques used to label cells for detection of infection and bleeding using nuclear scans for in vivo scanning. also we are using technetium instead of fdg which has very little radioactivity allowing us to work with the current cardiac labs with out having to reconstruct the labs with special shielding for radioactive compounds. real benefit of stem cells then can be explored after demonstrating the proper homing.

phase one: four different types of stem cells will be tested ( freshly aspirated bone marrow cells, cryopreserved cells, umbilical cord cells, stem cells mobilised from bone marrow by g-csf, mesenchymal cells), and the efficacy of labelling documented and effect on viability noted. 3 samples of each type will be tested and the results will be documented. different cells are being tried to test the efficiency of the labelling technique in different types of cells. this will provide the protocols for all future labelling studies. this will be conducted in collaboration between the stem cell department, nuclear medicine department and nuclear cardiology department. phase two (clinical study): this will be the pilot clinical study done alongside with the phase one study, and will enrol 10 patients with recent myocardial infarction ( within 3 months) . a small fraction of patient's own bone marrow stem cells will be labelled with technetium 99m hmpao. the labelled cells will be administered via the intracoronary injection along with the unlabeled stem cells. the localization of the radio-labelled stem cells in the myocardium will then be detected using the conventional gamma camera.

Eligibility criteria:
inclusion criteria: * myocardial infarction (\< three months) with either angioplasty or thrombolysis done to open the infarct causing artery. * patent coronary arteries after the infarct * left ventricular dysfunction (ejection fraction \< 50%) exclusion criteria: * ongoing infection * obstructive coronary disease * history of symptoms more than 3 months * any evidence of malignancy or other systemic illness. * cell yield less than 10 million cells
warfarin versus aspirin recurrent stroke study

Conditions: Stroke

Summary: the goal of this study is to compare aspirin to warfarin for the prevention of recurrent stroke.

this study compared aspirin to warfarin to determine optimal therapy for the prevention of recurrent stroke. both drugs slow clotting of the blood. blood clots are involved in the final stages of the most common type of stroke due to blockage of the vessels that supply oxygen-rich blood to the brain. aspirin affects the blood platelets, while warfarin inhibits circulating clotting proteins in the blood. numerous previous studies have proven that use of aspirin reduces recurrent stroke by about 25 percent. part of the controversy about aspirin versus warfarin for stroke prevention has been the thinking among clinicians that warfarin may be a better blood thinner than aspirin to prevent almost all forms of stroke, but that it has greater side effects, increased risk of hemorrhage, and higher costs due to the need for blood tests to monitor the treatment effect for patients. to make the aspirin and warfarin arms of the study as unbiased as possible, the investigators matched both groups of patients for primary stroke severity, age, gender, education, and race/ethnicity. the two groups were also matched for stroke risk factors, including hypertension, diabetes, cardiac disease, smoking, alcohol consumption, and physical activity. the investigators used an aspirin dose of 325 mg/day and a warfarin dose specifically tailored to each individual patient. this study found that aspirin works as well as warfarin in helping to prevent recurrent strokes in most patients.

Eligibility criteria:
inclusion: * acceptable candidates for warfarin therapy * had an ischemic stroke within the previous 30 days * had scores of 3 or more on the glasgow outcome scale exclusion: * base-line inr above the normal range (more than 1.4) * history of stroke due to a procedure or that was attributed to high-grade carotid stenosis for which surgery was planned * history of stroke associated with an inferred cardioembolic source

Keywords: stroke aspirin warfarin
ufpti 2403-pr12: real-time volumetric ionizing radiation acoustic imaging for in-vivo proton treatment monitoring in pencil-beam scanning

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate the use of ionizing-radiation photo acoustic imaging (irai) for proton radiation treatment.


Eligibility criteria:
inclusion criteria: * disease: prostate cancer * treatment site: * prostate or prostate and seminal vesicle * no regional lymph node is involved * patient's body weight: patient's body weight is less than 350 lbs to consider the total weight limit that the proteusone treatment table and the robotic arm can operate * treatment volume size: maximum size less than 15 x 15 cm in a cross-section and a thickness less than 20 cm to consider 2d transducer matrix size * provision to sign the consent form and understand the non-invasiveness of irai * patient agreement on tolerance on placing a water bag to acquire irai during treatment * treatment modality: proton radiation therapy with ufhpti's proteusone gantry using pbs exclusion criteria: * a patient who would not be tolerable or will feel nervous about being touched on the skin with a water bag * a patient with a significant medical implant or hardware in the treatment area
atypical antipsychotics in improvement of quality of life in bipolar disorder

Conditions: Naturalistic; Observational

Summary: the purpose of this study is to reassure the clinical study data on atypical antipsychotics effect on quality of life in korean bipolar patients.


Eligibility criteria:
inclusion criteria: * the patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent. * meet dsm-iv-tr criteria for bipolar disorder (bipolar i disorder, bipolar ii disorder) at the time of baseline. exclusion criteria: * serious or unstable, medical illness. subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history. * known intolerance for or lack of response to atypical antipsychotics , as judged by the investigator.

Keywords: bipolar atypical antipsychotics quality of life observational
salvage therapy with idarubicin in relapsing cns lymphoma

Conditions: Lymphoma, B-Cell

Summary: the main objective of the trial is to assess the therapeutic activity of idarubicin as salvage treatment in patients with recurrent or progressive lymphoma in the central nervous system.


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of non-hodgkin's lymphoma * disease exclusively localised into the cns at first diagnosis and failure * progressive or recurrent disease * previous treatment with hdmtx containing cht and/or rt * presence of at least one target lesion, bidimensionally measurable * age 18 - 75 years * ecog performance status \< 3 (appendix 1). * no known hiv disease or immunodeficiency * hbsag-negative and ab anti-hcv-negative patients. * adequate bone marrow function (plt \> 100000 mm3, hb \> 9 g/dl, anc \> 2.000 mm3) * adequate renal function (serum creatinine \< 2 times unl) * adequate hepatic function (sgot/sgpt \< 3 times unl, bilirubin and alkaline phosphatase \< 2 times unl) * adequate cardiac function (vef ≥ 50%) * absence of any psycological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * non-pregnant and non-lactating status for female patients. adequate contraceptive measures during study participation for sexually active patients of childbearing potential. * no previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease since at least 5 years. * no concurrent treatment with other experimental drugs. * informed consent signed by the patient before registration
a study to evaluate the efficacy and safety of gefapixant (mk-7264) in women with endometriosis-related pain (mk-7264-034)

Conditions: Endometriosis-related Pain

Summary: the purpose of this study is to evaluate the efficacy, safety, and tolerability of gefapixant (mk-7264) in premenopausal female participants with moderate to severe endometriosis-related pain. the primary hypothesis: gefapixant is superior to placebo in reducing the average daily pelvic pain score (cyclic and non-cyclic, combined) during treatment cycle 2.


Eligibility criteria:
inclusion criteria: * has been surgically (laparoscopy or laparotomy) diagnosed with endometriosis. * has cyclic and non-cyclic, moderate to severe endometriosis-related pelvic pain (overall pelvic pain score ≥5 using a 0-10 nrs, with 0 representing no pain and 10 representing extremely severe pain). * has had spontaneous menstrual cycles before visit 1. * has body mass index (bmi) between 18 kg/m\^2 to 40 kg/m\^2 at visit 1. * is not pregnant, not breastfeeding, and agrees to follow the contraceptive guidance. * must agree to switch from her usual analgesic medication to only that which is permitted in the study. exclusion criteria: * history of hysterectomy and/or bilateral oophorectomy. * has undiagnosed vaginal bleeding. * has chronic, non-pelvic pain not caused by endometriosis that requires chronic analgesic. * has a clinically significant gynecologic condition identified in the screening evaluation. * has a history of anaphylaxis or cutaneous adverse drug reaction (with or without systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs. * has a known allergy/sensitivity or contraindication to gefapixant or its excipients. * has an allergy/sensitivity/intolerance to naproxen sodium (rescue medication) or any contraindication to its use, or has experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (nsaids). * has a history of endometriosis-related pain that was non-responsive to treatment with combined hormonal contraceptives (chcs), gonadotropin-releasing hormone (gnrh) antagonists, gnrh agonists, progestins, or aromatase inhibitors. * has a positive urine pregnancy test at any time before randomization. * has required more than 2 weeks of continuous use of narcotics for treatment of endometriosis-related pain within 6 months of visit 1.
registry of amniotic membrane: evaluating utilization and outcomes in various applications

Conditions: Orthopedic Disorder; Wound

Summary: this registry will assess clinical outcomes following the use of cryopreserved amniotic membrane (cam) for the treatment of orthopedic and various other conditions. this registry will collect outcomes data via a registry of up to 100 patients who have received treatment with cam in the post-market setting. patients will be enrolled from up to five healthcare centers.

the objective of this registry is to collect outcomes data via a registry on the uses of cam in the post-market setting, including: * adverse events related to the treatment, or the product, will be collected for up to 12 weeks following the treatment. * improvements in appropriate effectiveness markers for cam use in patients treated for various conditions. * improvements in overall quality of life resulting from cam treatment in patients. an additional objective is to determine standard of care follow-up for the target treatments, including effectiveness metrics used and typical follow-up schedule. this registry is intended to collect clinical data from patients for analysis purposes only and will not be used to treat patients. the plan does not allow for any deviation from standard of care practice. therefore, there is no added risk to patients from participating in the registry. the sponsor will use an electronic data capture (edc) system for capturing all the data from the sites. the system will be built and validated prior to initiation of the sites. each participating physician or appropriately trained designee shall enter data into the edc system, providing all applicable data and documentation to the sponsor. data will be reviewed for missing data, data consistency, and reasonableness of responses. discrepancies will be resolved through a formal query process within the edc system, and may involve direct contact with hospital staff. the conduct of the registry will be supervised through a process of centralized and on-site monitoring. the sponsor may remotely monitor the registry for data completeness and for adverse events. on-site monitoring will be implemented as necessary throughout the course of the registry. the physician/clinic will provide direct access to source data/documents for registry-related monitoring, audits and irb review.

Eligibility criteria:
inclusion criteria: • a patient is suitable for inclusion in this registry if the patient has been treated with cam for any indication as per the standard of care practice. exclusion criteria: • patients are excluded from registry enrollment if they are under the age of 22 years.
high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor (car) modified t-cells directed against cd19+ b-cells for relapsed and refractory aggressive b cell non-hodgkin lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: the purpose of this study is to test the safety of delivering the patients' own immune cells, called t cells, after the high-dose chemotherapy (hdt) and autologous stem cell transplantation (asct).


Eligibility criteria:
transplant eligible patients will be eligible if criteria met per below. inclusion criteria: * patients ≥ 18 years of age with aggressive b-cell non-hodgkin lymphoma subtypes including, relapsed or refractory diffused large b-cell lymphoma (dlbcl), and transformed follicular lymphoma meeting at least one of the following criteria: * bone marrow involvement at the time of relapse or refractory disease and not appropriate for allogeneic transplantation. * pet positive disease outside of one radiation port unless single-port disease treated with prior radiotherapy within the port, following \> or = to 2 cycles of salvage chemotherapy, still achieving chemosensitive status 1999 iwg criteria (section 12.2 and 12.383). * creatinine ≤ 1.5 mg/100 ml (or measured 24 hour creatinine clearance of ≥ 50 cc/min) * bilirubin \<2.0 mg/100 ml, ast and alt \<3x the upper-limit of normal, pt and ptt \< 2x normal outside the setting of stable chronic anticoagulation therapy, * adequate cardiac function (lvef\>40%) as assessed by echo or muga scan performed within 1 month of treatment. * adequate pulmonary function as assessed by dlco of \> or = to 45% adjusted for hemoglobin. * life expectancy of \> 3 months. exclusion criteria: * karnofsky performance status ≤ 70 (see appendix vi). * patients with other aggressive b-cell malignancies including, but not limited to: burkitt lymphoma, transformed cll/sll and transformed marginal zone lymphoma that are not included in 6.1 inclusion criteria. * patients previously treated with autologous or allogeneic bone marrow or stem cell transplantation are ineligible. * other past or current malignancy unless in the opinion of the investigator it does not contraindicate participation in the study. * uncontrolled bacterial, viral or fungal infection. * patients with hiv, active hepatitis b or hepatitis c infection.

Keywords: relapsed refractory autologous stem cell transplantation high dose chemotherapy 19-28z t cells/kg 12-117
identification of new prognostic markers in psoriatic arthritis

Conditions: Psoriasis; Psoriatic Arthritis

Summary: identification of possible markers associated with the onset and / or progression of psoriatic arthritis through comparison in patients with psoriasis alone (ps) and patients with psoriasis with joint involvement (psa), plasma levels of a panel of cytokines referable to the th17 pathway , together with serum levels of mmps, timps and markers of bone remodeling. the primary objective of this study is to verify whether the arthropathy component has an effect on the metabolic activity of osteoblasts. this will be determined through the study of the differences in serum concentrations, between ps and psa subjects, of "ctx", the parameter best characterized in terms of analytical variability and intra- and inter-individual variability, in the field of bone metabolism. the secondary objective is the verification of the differences in serum concentrations of the series of parameters specified above, in order to define a complete pattern of variations that can identify the molecular pathways involved in the definition of psoriatic arthropathy.


Eligibility criteria:
inclusion criteria: * age ≥18 years * for ps group: plaque psoriasis no previous treatment with biological drugs - for psa group: plaque psoriasis with arthropathy no previous treatment with biological drugs but in treatment as per clinical practice or, alternatively, last treatment with drug suspended by a number of days double compared to the half-life of the drug exclusion criteria: * age \<18 years * pregnancy * neoplasia in progress or previous (\<5 years) * other acute or chronic inflammatory diseases * other rheumatological diseases * metabolic diseases of the primitive bone * recent bone fractures (\<6 months) * anxiety, psychosis, depressive disorders * inability to understand the information provided by the recruiter doctor * for ps group: treatment with biological drugs
ultrasound assessment of entheseal sites in patients with seronegative spondyloarthropathy with or without fibromyalgia

Conditions: Spondyloarthropathy; Fibromyalgia

Summary: seronegative spondyloarthropathies are a family of joint disorders that classically include ankylosing spondylitis (as), psoriatic arthritis (psa), inflammatory bowel disease (ibd) associated arthritis, reactive arthritis (formerly reiter syndrome; rea), and undifferentiated spa. enthesitis, or inflammation of the sites where the tendons or ligaments insert into the bone, is a key pathological finding in spa . it is considered the hallmark and characteristic feature of spondyloarthritis (spa). entheses could be classified as fibrous entheses and fibrocartilaginous entheses. regional structural damage, such as tendon injuries and bone erosions, are frequently caused by persistent enthesitis. the healing process that follows may result in the emergence of enthesophytes and, eventually, functional impairment of related anatomic structures. imaging modalities for evaluating entheseal lesions include conventional radiology, bone scintigraphy, magnetic resonance imaging (mri) and power doppler (pd) ultrasound (us). us has its own unique advantage in the diagnosis of enthesitis in as; it uses a high-frequency or ultra-high-frequency probe that effectively visualizes the internal structure of the tendon and is recognized as the gold standard for tendon involvement. it is superior to clinical examination in the detection of peripheral enthesitis. manifestations of tendon enthesitis in spa on us include a thickened tendon, hypoechoicity, local calcification and bony erosion. abnormal blood flow in tendon entheseal sites can be detected by power doppler us. fibromyalgia (fm) is a syndrome characterized by chronic musculoskeletal pain. the main symptoms of which are muscle stiffness, joint stiffness, insomnia, fatigue, mood disorders, cognitive dysfunction, anxiety, depression, general sensitivity and the inability to carry out normal daily activities \[8, 9\]. it can also be associated with specific diseases, such as infections, diabetes, rheumatic diseases and psychiatric or neurological disorders. smythe and moldofsky later developed the name "fibromyalgia" after identifying "pain points," which are areas of severe tenderness. these points are defined as areas of hyperalgesia/allodynia when a pressure of about 4 kg causes pain.


Eligibility criteria:
inclusion criteria: * patients fulfill the assessment in spondyloarthrits international society (asas) classification criteria for axial spondyloarthritis. * age above 18 years old. * patient cooperative and can answer questions. * patients who are able and willing to give written informed consent. exclusion criteria: * other rheumatologic or collagen diseases. * age below 18 years and above 60 years. * uncooperative patients. * patient not able and willing to give written informed consent.

Keywords: spondyloarthropathy fibromyalgia enthesitis ultrasound
nutritional supplementation with agmatine sulfate during small fiber neuropathy

Conditions: Peripheral Neuropathy

Summary: this is a nonblinded case-only study that evaluates the effects of agmatine sulfate on small fiber peripheral neuropathy. patients will be started on agmatine sulfate (a metabolite of arginine) and monitored for two months. improvement will be noted on their response to the neuropathic pain questionnaire. additionally the investigators will note improvement by performing autonomic function testing at the beginning and end of the study.


Eligibility criteria:
inclusion criteria: * men and women ages 18-75 with symptoms of small fiber neuropathy and have been diagnosed via autonomic function testing and or skin biopsy exclusion criteria: * women who are pregnant or breast feeding, patients with history of substance abuse, and patients with myelopathy
the effect of two different video showings on pain and anxiety in children undergoing adenotonsillectomy

Conditions: Pain After Adenotonsillectomy

Summary: purpose of the research: the purpose of the research is to examine the effect of two different video presentations on pain and anxiety in children undergoing adenotonsillectomy. type of research it is planned as a randomized controlled interventional type study to examine the effects of two different video presentations on pain and anxiety in children undergoing adenotonsillectomy.

technology is an indispensable part of our age and daily life . when we look at the research, it is seen that educational interventional preparation programs increase the harmony between both children, parents and health professionals. the increase in children's self-control and the elimination of unrealistic expectations may be related to the trust in healthcare professionals. studies indicate that educational video animations are the most effective non-pharmacological method in reducing anxiety . video animations will be useful for children because they create sound and images. it is believed that video animations with educational content that are understandable to children are essential for children's education. it is believed that animation shown to children will reduce their anxiety.

Eligibility criteria:
inclusion criteria: * being between the ages of 6-12 * having adenotonsillectomy surgery * signing the informed consent form by the patient's legal guardian exclusion criteria: * not being between the ages of 6-12 * not having adenotonsillectomy surgery * failure to sign the enformel consent form by the patient's legal guardian

Keywords: pain,adenotonsillectomy,anxiety,children